Key Drivers
- High margins
- Unsustainable payout
- Very high leverage
AIAI Summary
ALX has pivoted from a steady high-yield REIT to a turnaround story where the primary investment catalyst is whether management uses Rego Park proceeds and its cash buffer to materially deleverage and cut an unsustainably high dividend rather than preserve payouts. Monitor actual net sale proceeds, explicit debt-paydown actions, and dividend re-calibration—if proceeds aren't used to reduce leverage, equity downside risk is material given ~9x debt/equity and rising short interest.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Unsustainable payout
- •Very high leverage
ALX shows strong operating profitability and solid free cash/cash reserves but is critically undermined by very high leverage, a dividend that far exceeds earnings, low asset turnover and rich earnings multiples.
Price Behavior
Key Price Behavior Insights:
- •Mid‑240s resistance
- •Mild downside bias
- •Support near $232
Over the last month ALX traded in a mid‑$240s resistance band (~$245–$250) but slid about 1% from $241.72 to $239.39, showing weakened momentum and risk down toward support near $232–$233.
Peak near $245.9 then quick pullback, including drop from $244.84 to $239.39 in one day
Sentiment & News
Key News Insights:
- •Property sale
- •$150M financing
- •Mid‑2027 data target
Alexander's sees liquidity and analyst/technical uplift from a $202M net property sale and upgrade, while ALX Oncology secures funding and clinical progress that extend its runway and set near-term milestones amid REIT sector weakness.
The Alexander's sale and ALX Oncology's financing materially de‑risk near-term balance‑sheet and program timelines, but REIT macro pressures could cap upside for the real estate name
Similar Companies in Real Estate
Other companies in the same sector with AI ratings